Sepracor says asthma drug data is favorable
13th Nov 2006, 22:28 GMT
Sepracor said a study found the company's asthma drug, Xopenex HFA, produced fewer adverse effects at high doses than another treatment, racemic albuterol HFA.
Sepracor says asthma drug data is favorable related news:
- Sepracor says asthma drug data is favorable — Latest news from Boston Business Journal
- Sepracor Presents Data on Asthma Drug — Operations-Related News from StratCenter.com
- New Survey Data Reveal Majority of Asthma Patients Remain Uncontrolled Based on Scores from the Asthma Control Test — Physician News News from StratCenter.com
- AstraZeneca asthma aerosol improves lung function — Pharmaceutical Business Review Latest News
- The Global Initiative For Asthma (GINA) Announces Major Changes In Its Guidance For Asthma Management And Prevention — Health News from Medical News Today
- Effective Asthma Management Strategies Linked to Better Long-term Asthma Control — Medscape Medical News Headlines
- Favrille drug fails secondary goal — Pharmaceutical Business Review Latest News
- Approved Asthma Therapy SYMBICORT Improves Lung Function Safely And Effectively — Health News from Medical News Today
- ACAAI: Rodent Exposure Linked to High Asthma Rates in Children — MedPage Today.com Latest Headlines
- New Studies Reveal What Caregivers See as Key Issues to Facilitate Better Asthma Treatment — Government/ Industry Regulation News from StratCenter.com
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies
- Kos' Swan Song